Cargando…

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

BACKGROUND: Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in the assessment of treatment response during chemotherapy but has never bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Fonseka, Duneesha, Arnold, David T., Stadon, Louise, Morley, Anna, Keenan, Emma, Darby, Michael, Armstrong, Lynne, Virgo, Paul, Maskell, Nick A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816389/ https://www.ncbi.nlm.nih.gov/pubmed/29454314 http://dx.doi.org/10.1186/s12885-018-4113-3

Ejemplares similares

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
por: Arnold, David T, et al.
Publicado: (2017)

Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study
por: Bibby, Anna C., et al.
Publicado: (2017)

Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma
por: De Fonseka, Duneesha, et al.
Publicado: (2022)

BTS guideline for the investigation and management of malignant pleural mesothelioma
por: Woolhouse, Ian, et al.
Publicado: (2018)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

A feasibility randomised trial comparing therapeutic thoracentesis to chest tube insertion for the management of pleural infection: results from the ACTion trial
por: Arnold, David T., et al.
Publicado: (2022)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
por: Zhang, Yi-Fan, et al.
Publicado: (2015)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)
por: Conway, Ruairi J H, et al.
Publicado: (2022)

Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma
por: Dipper, Alex, et al.
Publicado: (2021)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
por: Grosso, Federica, et al.
Publicado: (2021)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
por: He, Xiaoqing, et al.
Publicado: (2017)

Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells
por: Fujihira, Haruhiko, et al.
Publicado: (2021)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Preoperative Serum Levels of Mesothelin in Patients with Colon Cancer
por: Bostancı, Özgür, et al.
Publicado: (2014)

Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts
por: Macura, Sherrill L, et al.
Publicado: (2013)

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
por: Sato, Tadashi, et al.
Publicado: (2014)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Histology and ultrastructure of serially transplanted rat mesotheliomas.
por: Wagner, J. C., et al.
Publicado: (1982)

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
por: Bibby, Anna C., et al.
Publicado: (2016)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models
por: Alfaleh, Mohamed A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9m1u2qhvcqu26bvdmtpkkdbbgk